Edgewise Therapeutics (EWTX) GC nets RSU vesting, tax sales and new grants
Rhea-AI Filing Summary
Edgewise Therapeutics, Inc. General Counsel John R. Moore reported a mix of equity transactions on August 12, 2026. He exercised Restricted Stock Units into 12,499 shares of common stock and sold 5,016 shares in a sell‑to‑cover transaction to satisfy statutory tax withholding obligations. He also received new awards of 32,500 Restricted Stock Units vesting annually beginning August 12, 2027, and a stock option covering 65,000 shares, vesting monthly beginning September 12, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
10 txns
Insider
MOORE JOHN R
Role
General Counsel
Sold
5,016 shs ($220K)
Approx. gross sale proceeds
$220K
Approx. exercise cost
$0.00
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F6 | 5,781 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F7 | 6,718 | $0.00 | $0.00 |
| Grant/Award | Restricted Stock Units F8 | 32,500 | $0.00 | $0.00 |
| Grant/Award | Stock Option (Right to Buy) F9 | 65,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 5,781 | $0.00 | $0.00 |
| Exercise | Common Stock | 6,718 | $0.00 | $0.00 |
| Sale | Common Stock F1, F2 | 2,439 | $43.8081 | $107K |
| Sale | Common Stock F1, F3 | 59 | $44.4142 | $3K |
| Sale | Common Stock F1, F4 | 99 | $44.5019 | $4K |
| Sale | Common Stock F1, F5 | 2,419 | $43.7985 | $106K |
Holdings After Transaction:
Restricted Stock Units — 64,220 shares (Direct);
Stock Option (Right to Buy) — 65,000 shares (Direct);
Common Stock — 17,697 shares (Direct)
Footnotes (9)
- F1. Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person.
- F2. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.22 to $44.18, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.40 to $44.42, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $44.41 to $44.55, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $43.33 to $44.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2025.
- F7. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2026.
- F8. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
- F9. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.
Key Figures
RSUs converted to common stock: 12,499 shares
Shares sold to cover taxes: 5,016 shares
Average sale price block 1: $43.8081 per share
+3 more
6 metrics
RSUs converted to common stock
12,499 shares
Total underlying common shares from two RSU exercises on August 12, 2026
Shares sold to cover taxes
5,016 shares
Common stock sold in sell-to-cover transactions for statutory tax withholding
Average sale price block 1
$43.8081 per share
Average price for 2,439 shares sold, with trades from $43.22 to $44.18
New RSU grant
32,500 units
RSUs granted, vesting in four equal annual installments from August 12, 2027
New stock option grant
65,000 shares
Option over common stock, 1/48th vests monthly from September 12, 2026
Net buy/sell shares
-5,016 shares
Transaction summary net buy/sell direction reported as net-sell
Key Terms
Restricted Stock Units, sell-to-cover, statutory tax withholding obligations, contingent right, +1 more
5 terms
Restricted Stock Units financial
"Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
sell-to-cover financial
"to be funded by a "sell-to-cover" transaction and does not represent a discretionary"
Sell-to-cover is when part of newly issued or exercised company stock is immediately sold to pay required taxes and fees, so the recipient keeps the remaining shares. For investors this matters because it reduces the number of shares insiders or employees actually hold after a grant, can create small, routine share sales that aren’t signal of cashing out, and slightly increases share supply on the market—like selling a portion of a paycheck to cover the tax bill.
statutory tax withholding obligations financial
"shares sold to cover the statutory tax withholding obligations in connection with the vesting"
contingent right financial
"each of which represent a contingent right to receive one share of Edgewise"
Reporting Person financial
"subject to the Reporting Person continuing as a service provider through each vest date"
FAQ
What insider transactions did Edgewise Therapeutics (EWTX) report for John R. Moore?
On August 12, 2026, General Counsel John R. Moore exercised 12,499 RSUs into common stock, sold 5,016 shares to cover taxes, and received new equity awards of 32,500 RSUs plus a stock option for 65,000 shares.
What new RSU awards did John R. Moore receive from Edgewise Therapeutics (EWTX)?
He received 32,500 Restricted Stock Units, each representing a contingent right to one share of common stock. Footnote F8 explains these RSUs vest in four equal annual installments beginning on August 12, 2027, assuming continued service.
What are the terms of John R. Moore’s new stock option from Edgewise Therapeutics (EWTX)?
He was granted a stock option over 65,000 shares of common stock. Footnote F9 states that 1/48th of the shares vest each month beginning on September 12, 2026, contingent on him continuing as a service provider through each vest date.
Were John R. Moore’s Edgewise Therapeutics (EWTX) transactions under a Rule 10b5-1 trading plan?
The Form 4’s Rule 10b5‑1 checkbox is not checked (aff_10b5_one is false), and the footnotes do not reference any trading plan. The sales are described instead as sell-to-cover transactions for tax withholding on vested RSUs.
AI-generated analysis. How Rhea-AI works. Not financial advice.
